BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
CAMBRIDGE, Mass., December 03, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage medical device company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...